Celyad Oncology (LSE:0QFK) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

0QFK Overzicht aandelen

A biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer.

Over het bedrijf

0QFK fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

De winst is de afgelopen 5 jaar met 7.1% per jaar gegroeid

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft een omzet van minder dan 1 miljoen USD ( €102K )

Heeft minder dan 1 jaar cash runway

Aandelen zijn zeer illiquide

+ 1 meer risico

Celyad Oncology SA Concurrenten

BSF Enterprise

LSE:BSFA

UK£4.1m

ValiRx

AIM:VAL

UK£1.8m

SkinBioTherapeutics

AIM:SBTX

UK£24.0m

Theracryf

AIM:TCF

UK£3.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Celyad Oncology
Historische aandelenkoersen
Huidige aandelenkoers	€0.37
52 Week Hoogtepunt	€1.23
52 Week Laag	€0.35
Bèta	1.3
11 maand verandering	0%
3 maanden verandering	-0.27%
1 Jaar Verandering	-50.54%
33 jaar verandering	-93.48%
5 jaar verandering	-98.00%
Verandering sinds IPO	-98.79%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	0QFK	GB Biotechs	GB Markt
7D	0%	0.9%	-0.8%
1Y	-50.5%	-16.8%	9.2%

Rendement versus industrie: 0QFK presteerde slechter dan de UK Biotechs -sector, die het afgelopen jaar een rendement van -15.6 % opleverde.

Rendement versus markt: 0QFK presteerde slechter dan UK Market, dat het afgelopen jaar een rendement van 9.7 % opleverde.

Prijsvolatiliteit

Is 0QFK's price volatile compared to industry and market?
0QFK volatility
0QFK Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.1%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.4%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: 0QFK heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 0QFK in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2004	18	Michel E. Lussier	www.celyad.com

Celyad Oncology SA Samenvatting

Hoe verhouden de winst en inkomsten van Celyad Oncology zich tot de beurswaarde?
0QFK fundamentele statistieken
Marktkapitalisatie	€14.07m
Inkomsten(TTM)	-€8.45m
Inkomsten(TTM)	€102.00k

138.1x

P/S-verhouding

-1.7x

Koers/Winstverhouding

Is 0QFK overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
0QFK resultatenrekening (TTM)
Inkomsten	€102.00k
Kosten van inkomsten	€69.00k
Brutowinst	€33.00k
Overige uitgaven	€8.48m
Inkomsten	-€8.45m

Laatst gerapporteerde inkomsten

Dec 31, 2023

Volgende inkomensdatum

Aug 06, 2024

Winst per aandeel (EPS)	-0.20
Brutomarge	32.35%
Nettowinstmarge	-8,282.35%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 0QFK op de lange termijn?

Bekijk historische prestaties en vergelijking

0QFK Overzicht aandelen

Beloningen

Risicoanalyse

Celyad Oncology SA Concurrenten

LSE:BSFA

UK£4.1m

AIM:VAL

UK£1.8m

AIM:SBTX

UK£24.0m

AIM:TCF

UK£3.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Celyad Oncology Appoints Matt Kane as Chief Executive Officer, Effective October 1, 2024

Celyad Oncology SA to Report First Half, 2025 Results on Sep 25, 2025

Celyad Oncology SA to Report First Half, 2024 Results on Sep 20, 2024

Celyad Oncology SA to Report First Half, 2024 Results on Aug 06, 2024

Celyad Oncology Sa Announces Executive Change

Celyad Oncology SA announced that it has received €9.794 million in funding from CFIP CLYD (UK) Limited, Fortress Investment Group LLC, Tolefi S.A.

Recent updates

Celyad Oncology Appoints Matt Kane as Chief Executive Officer, Effective October 1, 2024

Celyad Oncology SA to Report First Half, 2025 Results on Sep 25, 2025

Celyad Oncology SA to Report First Half, 2024 Results on Sep 20, 2024

Celyad Oncology SA to Report First Half, 2024 Results on Aug 06, 2024

Celyad Oncology Sa Announces Executive Change

Celyad Oncology SA announced that it has received €9.794 million in funding from CFIP CLYD (UK) Limited, Fortress Investment Group LLC, Tolefi S.A.

Celyad Oncology SA ADR - Sponsored to Be Deleted from OTC Equity

Celyad Oncology SA, Annual General Meeting, May 06, 2024

Celyad Oncology SA to Report First Half, 2023 Results on Sep 04, 2023

Celyad Oncology SA announced that it expects to receive €9.794 million in funding from Fortress Investment Group LLC, Tolefi S.A., and other investors

Nasdaq to Delist the American Depositary Shares of Celyad Oncology

Celyad Oncology Receives Notification Letter from Nasdaq Regarding ADS's Scheduled for Delisting from The Nasdaq Global Market and to be Suspended at the Opening of U.S. Business on May 19, 2023

Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares from Nasdaq

Less than half of directors are independent

Celyad Oncology Announces Publication of Data from Its Phase 1 Think Study of CYAD-01

Celyad Oncology SA to Report Q1, 2023 Results on May 05, 2023

Less than half of directors are independent

Celyad Oncology SA to Report Q3, 2023 Results on Nov 09, 2023

Celyad Oncology Provides Update on Clinical Trial Programs

Cellistic emtered into asset purchase agreement to acquire Manufacturing Business Unit of Celyad Oncology from Celyad Oncology SA (ENXTBR:CYAD) for €6 million.

Less than half of directors are independent

Celyad Oncology Sa Announces Fda Lifts Clinical Hold of Cyad-101-002 Phase 1B Trial

Celyad Oncology SA Announces Chief Financial Officer Changes

Celyad Oncology SA Announces Board Changes

Less than half of directors are independent

Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial

Celyad Oncology SA Announces Voluntary Pause of CYAD-101-002 Phase 1B Trial

Celyad Oncology SA Announces Program Update and Anticipated Milestones for 2022

Celyad Oncology SA Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial

Celyad Oncology SA Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Meeting and Exposition

Celyad Oncology SA announced that it expects to receive €28.73 million in funding from Fortress Investment Group LLC

Forecast to breakeven in 2023

Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress

Celyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma At the European Hematology Association Virtual Congress

Full year 2020 earnings released: €1.23 loss per share (vs €2.29 loss in FY 2019)

Celyad Oncology SA to Report Fiscal Year 2020 Results on Mar 24, 2021

New 90-day low: €6.42

Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium

Celyad Oncology SA Appoints Marina Udier, Ph.D., to Board of Directors

Celyad Oncology SA announced that it expects to receive $40 million in funding from Lincoln Park Capital, LLC

Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 alloSHRINK Trial for mCRC

Celyad Oncology Announces Dosing of First Patient in Phase 1 IMMUNICY-1 Trial of CYAD-211 for Multiple Myeloma

New 90-day low: €7.56

Celyad Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 with KEYTRUDA® (pembrolizumab) in Patients with Microsatellite Stable mCRC

New 90-day low - €8.31

New 90-day low - €8.33

Earnings released

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Celyad Oncology SA Samenvatting

138.1x

-1.7x

Inkomsten en omzet